In a preclinical trial of liver disease, treatment with C/EBP α small activating RNA (saRNA) has shown significant clinical promise by reducing tumor volume and improving essential biomarkers of liver function, such as alanine transaminase, aspartate aminotransferase, bilirubin and albumin (Reebye et al., 2014; Zhao et al., 2017). The gene discussed is CEBPA; the disease is neoplasm.